1 | updated | 2,455 |
2 | expanded | 1,728 |
3 | up-to-date | 422 |
4 | abbreviated | 335 |
5 | medicus | 87 |
6 | 8-item | 26 |
7 | restructured | 17 |
8 | interspaced | 11 |
9 | archie | 9 |
10 | all-encompassing | 6 |
11 | concocted | 6 |
12 | encryption | 6 |
13 | up-dated | 5 |
14 | 2005-6 | 4 |
15 | language-restricted | 4 |
16 | self-antigen | 4 |
17 | study.in | 4 |
18 | individual-patient-data | 3 |
19 | lorenz | 3 |
20 | overweighed | 3 |
21 | assessment-cancer | 2 |
22 | b-long | 2 |
23 | electrogram-based | 2 |
24 | ep-related | 2 |
25 | exablate | 2 |
26 | fda-mandated | 2 |
27 | g-drg | 2 |
28 | immunornase | 2 |
29 | ipf-specific | 2 |
30 | japanese-language | 2 |
31 | ldl-ch/hdl-ch | 2 |
32 | thaumarchaeal | 2 |
33 | ultraseek | 2 |
34 | value-free | 2 |
35 | 0.97+/-1.34 | 1 |
36 | 120.9+/-40.5 | 1 |
37 | 2-taiwan | 1 |
38 | 2.2+/-0.5l/min/m | 1 |
39 | 22,715 | 1 |
40 | 25.9±1.2kg/m | 1 |
41 | 34±7kg·m | 1 |
42 | 37.9+/-20.5 | 1 |
43 | 49.4±17.8ml/m | 1 |
44 | 91.3/h | 1 |
45 | a-proteobacterium | 1 |
46 | analysis-by-patient | 1 |
47 | arrow-word | 1 |
48 | asvp | 1 |
49 | c3d/c3 | 1 |
50 | carruthers | 1 |
51 | central-the | 1 |
52 | h-fac | 1 |
53 | hemibiotroph | 1 |
54 | illness-phase-specific | 1 |
55 | individual-participant-data | 1 |
56 | inventory-chinese | 1 |
57 | low.both | 1 |
58 | lvet/qt | 1 |
59 | marik | 1 |
60 | mean≥4.00 | 1 |
61 | mirror-flipped | 1 |
62 | muscular/ligamentous | 1 |
63 | m±sd=31.5±2.7kg/m | 1 |
64 | nucleodur | 1 |
65 | ovid-based | 1 |
66 | physical/functional/breast | 1 |
67 | pirogov | 1 |
68 | post-sich | 1 |
69 | pplvmass | 1 |
70 | program-japanese | 1 |
71 | recruitment-began | 1 |
72 | scale-chinese | 1 |
73 | sought.this | 1 |
74 | spanish-translated | 1 |
75 | strategy.methods | 1 |
76 | study-was | 1 |
77 | subgroups-based | 1 |
78 | test-simplified | 1 |
79 | ultrahemofilter | 1 |
80 | underpowered.this | 1 |
81 | values-with | 1 |
82 | venouscatheter | 1 |
83 | wendy | 1 |
84 | widely-circulated | 1 |
1 | 0.97+/-1.34 | 1 |
2 | 120.9+/-40.5 | 1 |
3 | 2-taiwan | 1 |
4 | 2.2+/-0.5l/min/m | 1 |
5 | 2005-6 | 4 |
6 | 22,715 | 1 |
7 | 25.9±1.2kg/m | 1 |
8 | 34±7kg·m | 1 |
9 | 37.9+/-20.5 | 1 |
10 | 49.4±17.8ml/m | 1 |
11 | 8-item | 26 |
12 | 91.3/h | 1 |
13 | a-proteobacterium | 1 |
14 | abbreviated | 335 |
15 | all-encompassing | 6 |
16 | analysis-by-patient | 1 |
17 | archie | 9 |
18 | arrow-word | 1 |
19 | assessment-cancer | 2 |
20 | asvp | 1 |
21 | b-long | 2 |
22 | c3d/c3 | 1 |
23 | carruthers | 1 |
24 | central-the | 1 |
25 | concocted | 6 |
26 | electrogram-based | 2 |
27 | encryption | 6 |
28 | ep-related | 2 |
29 | exablate | 2 |
30 | expanded | 1,728 |
31 | fda-mandated | 2 |
32 | g-drg | 2 |
33 | h-fac | 1 |
34 | hemibiotroph | 1 |
35 | illness-phase-specific | 1 |
36 | immunornase | 2 |
37 | individual-participant-data | 1 |
38 | individual-patient-data | 3 |
39 | interspaced | 11 |
40 | inventory-chinese | 1 |
41 | ipf-specific | 2 |
42 | japanese-language | 2 |
43 | language-restricted | 4 |
44 | ldl-ch/hdl-ch | 2 |
45 | lorenz | 3 |
46 | low.both | 1 |
47 | lvet/qt | 1 |
48 | marik | 1 |
49 | mean≥4.00 | 1 |
50 | medicus | 87 |
51 | mirror-flipped | 1 |
52 | muscular/ligamentous | 1 |
53 | m±sd=31.5±2.7kg/m | 1 |
54 | nucleodur | 1 |
55 | overweighed | 3 |
56 | ovid-based | 1 |
57 | physical/functional/breast | 1 |
58 | pirogov | 1 |
59 | post-sich | 1 |
60 | pplvmass | 1 |
61 | program-japanese | 1 |
62 | recruitment-began | 1 |
63 | restructured | 17 |
64 | scale-chinese | 1 |
65 | self-antigen | 4 |
66 | sought.this | 1 |
67 | spanish-translated | 1 |
68 | strategy.methods | 1 |
69 | study-was | 1 |
70 | study.in | 4 |
71 | subgroups-based | 1 |
72 | test-simplified | 1 |
73 | thaumarchaeal | 2 |
74 | ultrahemofilter | 1 |
75 | ultraseek | 2 |
76 | underpowered.this | 1 |
77 | up-dated | 5 |
78 | up-to-date | 422 |
79 | updated | 2,455 |
80 | value-free | 2 |
81 | values-with | 1 |
82 | venouscatheter | 1 |
83 | wendy | 1 |
84 | widely-circulated | 1 |
1 | mean≥4.00 | 1 |
2 | c3d/c3 | 1 |
3 | 0.97+/-1.34 | 1 |
4 | 37.9+/-20.5 | 1 |
5 | 120.9+/-40.5 | 1 |
6 | 22,715 | 1 |
7 | 2005-6 | 4 |
8 | individual-participant-data | 1 |
9 | individual-patient-data | 3 |
10 | h-fac | 1 |
11 | illness-phase-specific | 1 |
12 | ipf-specific | 2 |
13 | interspaced | 11 |
14 | expanded | 1,728 |
15 | overweighed | 3 |
16 | test-simplified | 1 |
17 | mirror-flipped | 1 |
18 | restructured | 17 |
19 | ovid-based | 1 |
20 | electrogram-based | 2 |
21 | subgroups-based | 1 |
22 | up-dated | 5 |
23 | fda-mandated | 2 |
24 | updated | 2,455 |
25 | abbreviated | 335 |
26 | ep-related | 2 |
27 | spanish-translated | 1 |
28 | widely-circulated | 1 |
29 | language-restricted | 4 |
30 | concocted | 6 |
31 | arrow-word | 1 |
32 | value-free | 2 |
33 | japanese-language | 2 |
34 | central-the | 1 |
35 | archie | 9 |
36 | immunornase | 2 |
37 | program-japanese | 1 |
38 | scale-chinese | 1 |
39 | inventory-chinese | 1 |
40 | up-to-date | 422 |
41 | exablate | 2 |
42 | all-encompassing | 6 |
43 | b-long | 2 |
44 | g-drg | 2 |
45 | 91.3/h | 1 |
46 | ldl-ch/hdl-ch | 2 |
47 | post-sich | 1 |
48 | hemibiotroph | 1 |
49 | values-with | 1 |
50 | low.both | 1 |
51 | ultraseek | 2 |
52 | marik | 1 |
53 | thaumarchaeal | 2 |
54 | 25.9±1.2kg/m | 1 |
55 | m±sd=31.5±2.7kg/m | 1 |
56 | 49.4±17.8ml/m | 1 |
57 | 2.2+/-0.5l/min/m | 1 |
58 | 8-item | 26 |
59 | a-proteobacterium | 1 |
60 | 34±7kg·m | 1 |
61 | recruitment-began | 1 |
62 | 2-taiwan | 1 |
63 | self-antigen | 4 |
64 | study.in | 4 |
65 | encryption | 6 |
66 | asvp | 1 |
67 | assessment-cancer | 2 |
68 | venouscatheter | 1 |
69 | ultrahemofilter | 1 |
70 | nucleodur | 1 |
71 | study-was | 1 |
72 | strategy.methods | 1 |
73 | underpowered.this | 1 |
74 | sought.this | 1 |
75 | carruthers | 1 |
76 | pplvmass | 1 |
77 | medicus | 87 |
78 | muscular/ligamentous | 1 |
79 | analysis-by-patient | 1 |
80 | lvet/qt | 1 |
81 | physical/functional/breast | 1 |
82 | pirogov | 1 |
83 | wendy | 1 |
84 | lorenz | 3 |